{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T07:15:10Z","timestamp":1767165310834,"version":"build-2238731810"},"reference-count":10,"publisher":"BMJ","issue":"8","license":[{"start":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T00:00:00Z","timestamp":1629763200000},"content-version":"unspecified","delay-in-days":23,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2021,8,4]]},"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:p>Myeloid growth factors, either granulocyte colony-stimulating factor (CSF) or granulocyte-macrophage CSF, are widely used to reduce the incidence and severity of chemotherapy-induced neutropenia by prophylactic or therapeutic administration. However, their activity in the novel therapeutic regimens, which often rely on the association between immunotherapy and chemotherapy, has not been thoroughly characterized yet. This paper presents some of the preclinical and clinical research regarding the putative interplay between myeloid growth factors and the immune system, advocating further studies to elucidate their potential positive or negative consequences on the outcomes when administered with immunotherapeutic agents.<\/jats:p>","DOI":"10.1136\/jitc-2021-003154","type":"journal-article","created":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T12:30:50Z","timestamp":1629808250000},"page":"e003154","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Not all hematopoietic growth factors are created equal: should we gain information for their use with immunotherapy?"],"prefix":"10.1136","volume":"9","author":[{"given":"Paolo","family":"Bossi","sequence":"first","affiliation":[{"name":"Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, Universit\u00e0 degli Studi di Brescia, Brescia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Gurizzan","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, Universit\u00e0 degli Studi di Brescia, Brescia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Lorini","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, Universit\u00e0 degli Studi di Brescia, Brescia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1975-0923","authenticated-orcid":false,"given":"Pierluigi","family":"di Mauro","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, Universit\u00e0 degli Studi di Brescia, Brescia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Sardini","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, Universit\u00e0 degli Studi di Brescia, Brescia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Merlano","sequence":"additional","affiliation":[{"name":"Experimental Cell Therapy Lab, Medical Oncology Department, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2021,8,24]]},"reference":[{"key":"2025100313093960000_9.8.e003154.1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ejca.2018.07.129","article-title":"Haematological toxicities with immunotherapy in patients with cancer: a systematic review and meta-analysis","volume":"103","author":"Petrelli","year":"2018","journal-title":"Eur J Cancer"},{"key":"2025100313093960000_9.8.e003154.2","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/cam4.239","article-title":"A role for G-CSF and GM-CSF in nonmyeloid cancers","volume":"3","author":"Aliper","year":"2014","journal-title":"Cancer Med"},{"key":"2025100313093960000_9.8.e003154.3","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0902280106"},{"key":"2025100313093960000_9.8.e003154.4","first-page":"1541","article-title":"Granulocyte colony-stimulating factor expression as a prognostic biomarker in non-small cell lung cancer","volume":"25","author":"Stathopoulos","year":"2011","journal-title":"Oncol Rep"},{"key":"2025100313093960000_9.8.e003154.5","doi-asserted-by":"crossref","DOI":"10.1186\/1752-1947-8-147","article-title":"Leukemoid reaction and autocrine growth of bladder cancer induced by paraneoplastic production of granulocyte colony-stimulating factor--a potential neoplastic marker: a case report and review of the literature","volume":"8","author":"Kumar","year":"2014","journal-title":"J Med Case Rep"},{"key":"2025100313093960000_9.8.e003154.6","doi-asserted-by":"publisher","DOI":"10.1089\/jir.2014.0149"},{"key":"2025100313093960000_9.8.e003154.7","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.13943"},{"key":"2025100313093960000_9.8.e003154.8","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl158"},{"key":"2025100313093960000_9.8.e003154.9","doi-asserted-by":"crossref","first-page":"16025","DOI":"10.1038\/sigtrans.2016.25","article-title":"A novel cancer vaccine with the ability to simultaneously produce anti-PD-1 antibody and GM-CSF in cancer cells and enhance Th1-biased antitumor immunity","volume":"1","author":"Tian","year":"2016","journal-title":"Signal Transduct Target Ther"},{"key":"2025100313093960000_9.8.e003154.10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.3377"}],"updated-by":[{"DOI":"10.1136\/jitc-2021-003154corr1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T00:00:00Z","timestamp":1636934400000}}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2021-003154","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T20:09:46Z","timestamp":1759522186000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2021-003154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":10,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,8,24]]},"published-print":{"date-parts":[[2021,8]]}},"alternative-id":["10.1136\/jitc-2021-003154"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2021-003154","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8]]}}}